Duration of Maintenance Therapy Studied in Childhood ALL
MONDAY, Aug. 2, 2021 -- For patients with low-risk childhood acute lymphoblastic leukemia, the omission of seven pulses of therapy with vincristine and oral dexamethasone during the second year of maintenance therapy might not worsen treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 2, 2021 Category: Pharmaceuticals Source Type: news

Eliminating RNA-binding protein improves survival in aggressive leukemia
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer ’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at theUCLA Jonsson Comprehensive Cancer Center.The research,published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 — especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.In these ML...
Source: UCLA Newsroom: Health Sciences - July 29, 2021 Category: Universities & Medical Training Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news

New discoveries reveal how acute myeloid leukemia walks line between growth and cell death
(University of Chicago) Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news

Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for July 14, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Inhibitory effects of Tomivosertib in acute myeloid leukemia
(Impact Journals LLC) These Oncotarget findings demonstrate that Tomivosertib exhibits potent anti-leukemic properties on AML cells and support the development of clinical translational efforts involving the use of this drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Unraveling the mechanisms that create the individualized metabolism in leukemia
(Kumamoto University) Lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. New findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

Hypomethylating Agents in Children With Relapsed/Refractory AML Hypomethylating Agents in Children With Relapsed/Refractory AML
Hypomethylating agents can serve as a bridge to transplant for children and young adults with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Scientists uncover new mechanism that enables development of cancer
(UNC Lineberger Comprehensive Cancer Center) Researchers at the University of North Carolina at Chapel Hill have uncovered a mechanism that activates specific genes, leading to the development of cancers. They showed that a mutation that fuses two unrelated genes can promote a process similar to that observed when oil and water are mixed but do not blend together. The process, called liquid-liquid phase separation, can promote cancers such as acute leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2021 Category: Cancer & Oncology Source Type: news

Incidence Rates of Pediatric Cancers Vary by Race, Ethnicity
Variation seen by single year of age, including lower incidence of acute lymphoblastic leukemia in Blacks, especially at 1 to 7, 16 to 20 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 21, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Journal, Source Type: news

Reduced-Intensity Transplant Benefits Older Patients With AML Reduced-Intensity Transplant Benefits Older Patients With AML
Results from two large trials show that for older patients with acute myeloid leukemia (AML), survival is improved if they receive reduced-intensity conditioning before transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Media News - June 11, 2021 Category: Pharmaceuticals Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Investor Update - June 11, 2021 Category: Pharmaceuticals Source Type: news

1980 to 2017 Saw Improved Survival for Acute Myeloid Leukemia
THURSDAY, June 10, 2021 -- From 1980 to 2017, there was improvement in survival for acute myeloid leukemia (AML) in all age groups, except for those aged≥70 years, according to a study published in the June 15 issue of Cancer. Koji Sasaki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news

Venetoclax Shows Activity Against T-ALL in Children Venetoclax Shows Activity Against T-ALL in Children
Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia in children and young adults.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

When cancer cells " put all their eggs in one basket "
(Cold Spring Harbor Laboratory) Normal cells usually have multiple solutions for fixing problems that may arise. But cancer cells may " put all their eggs in one basket, " getting rid of all backup plans and depending on just one solution. CSHL Professor Christopher Vakoc's lab discovered that a particular type of blood cancer, acute myeloid leukemia, came to depend on a single DNA repair method. They developed a drug that shut down the remaining pathway in lab-grown cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Media News)
Source: Roche Media News - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - May 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

From mice to men: Study reveals potential new target for treating acute myeloid leukemia
(AlphaMed Press) A study released in STEM CELLS indicates that blocking transforming growth factor beta 1 (TGFβ1) could improve hematopoiesis in patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Combination therapy achieves high rates of response for patients with ALL
(University of Texas M. D. Anderson Cancer Center) A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

UAMS Researcher Gets $1.27M for Cancer Study
A researcher with the Winthrop P. Rockefeller Cancer Institute gets a five-year, $1.27 million grant to work toward developing two treatment options for acute myeloid leukemia patients. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 11, 2021 Category: American Health Source Type: news

Philip Schofield hails 'big step forward' cancer treatment that's saving lives
A GAME-CHANGING treatment for acute lymphoblastic leukaemia - a rare cancer of the blood cells - has been discovered. Philip Schofield remarked on the findings on ITV's This Morning on Monday. (Source: Daily Express - Health)
Source: Daily Express - Health - May 4, 2021 Category: Consumer Health News Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study finds potential therapeutic target for pediatric acute myeloid leukemia
(Nemours) Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children's Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
(University of Copenhagen - The Faculty of Health and Medical Sciences) T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this. Now, researchers from the University of Copenhagen have found a combination treatment that could benefit these patients and increase the survival rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

Healthcare use and costs for childhood acute lymphoblastic leukaemia differ by treatment protocol in Ontario, Canada
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

New genetic target for blood cancer treatment
(Wellcome Trust Sanger Institute) Researchers have identified a vulnerability in some cases of acute myeloid leukaemia that could be harnessed for targeted treatment of these poor-prognosis cancers (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

Steroids Unrelated to Psychological Reactions in Pediatric ALL
MONDAY, April 26, 2021 -- For children with acute lymphoblastic leukemia (ALL), the type/dose of steroid seems not to be related to adverse psychological reactions (APRs) but may be associated with sleep problems, according to a review published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2021 Category: Pharmaceuticals Source Type: news

Scientists develop new class of cancer drug with potential to treat leukaemia
(University of Cambridge) Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news

EU Panel Likes Azacitidine for AML Maintenance EU Panel Likes Azacitidine for AML Maintenance
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion of the drug for use as maintenance therapy in patients with acute myeloid leukemia.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

Children With Down Syndrome at Higher Risk for Leukemia
Risk particularly high for acute myeloid leukemia before age 5 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Pathology, Pediatrics, Radiology, Journal, Source Type: news

'Information theory' recruited to help scientists find cancer genes
(Johns Hopkins Medicine) Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2021 Category: Cancer & Oncology Source Type: news

Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
LEXINGTON, Mass., April 19, 2021 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food ... Biopharmaceuticals, Oncology, FDA Curis, acute myeloid leukemia, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2021 Category: Pharmaceuticals Source Type: news

Scientists identify potential drug candidates for deadly pediatric leukemia
(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates--JAK inhibitors and Mepron--hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Diet, Exercise Intervention Explored in Children With B-ALL
THURSDAY, April 8, 2021 -- For children with B-cell acute lymphoblastic leukemia (B-ALL), a diet and exercise intervention might improve disease response, according to a study published online April 1 in Blood Advances. Etan Orgel, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

What are the risk factors for experiencing side effects from childhood cancer treatments?
(Wiley) Steroids are essential for treating children with acute lymphoblastic leukemia, a type of cancer of the blood and bone marrow, but they can cause severe side effects such as psychological reactions and sleep problems. An analysis published in Psycho-Oncology of all relevant studies published to date indicates that there's insufficient high-quality research investigating the risk factors for these side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2021 Category: International Medicine & Public Health Source Type: news

Adding in Stem Cell Therapy Helps Beat a Common Childhood Leukemia
FRIDAY, April 2, 2021 -- Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new research suggests. Acute lymphoblastic leukemia is the most common... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 2, 2021 Category: General Medicine Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
In some cancers, including leukemia in children and adolescents, obesity can negatively affect survival outcomes. Obese young people with leukemia are 50% more likely to relapse after treatment than their lean counterparts.Now,a study led by researchers at UCLA and Children’s Hospital Los Angeles has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program imm...
Source: UCLA Newsroom: Health Sciences - April 1, 2021 Category: Universities & Medical Training Source Type: news

Stem cell transplants prevent relapses of most common childhood cancer
(University of Virginia Health System) Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2021 Category: Cancer & Oncology Source Type: news